Importance of renal function on prognostic value of cardiac iodine-123 metaiodobenzylguanidine scintigraphy

Annals of Nuclear Medicine

Volumn 21, Issue 1, 2007, Pages 57-63

  Furuhashi, Tatsuhiko ^a   Moroi, Masao ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Cardiac death; Cardiac sympathetic nerve function; Coronary artery disease; Dilated cardiomyopathy; Predictors

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

ADULT; AGED; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HUMAN; KAPLAN MEIER METHOD; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MORTALITY; MYOCARDITIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

EID: 33847103624     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03034000     Document Type: Article

References (25)

1. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in congestive heart failure: evidence of increased cardiorenal and total sympathetic nerve activity. Circulation 1986; 73: 615-621.
2. Cohn JN, Levine BT, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
3. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthome NH, et al. Myocardial imaging with radioiodinated norepinephrine storage analog. J Nucl Med 1981; 22: 22-31.
4. Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981; 22: 129-132.
5. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28: 1625-1636.
6. Schofer J, Spielmann R, Schuchert A, Weber K, Schuluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 12: 1252-1258.
7. Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988; 78: 1192-1199.
8. Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 1989; 30: 1182-1191.
9. Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995; 26: 1594-1599.
10. Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001; 42: 1757-1767.
11. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dore P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471-477.
12. Merlet P, Benvenuti C, Moyse D, Pouillant F, Dubois-Rande JL, Dural AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999; 40: 917-923.
13. 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun 1999; 20: 529-535.
14. 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart 2001; 86: 656-660.
15. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K; Ehime MIBG Heart Failure Study Investigators. Prognostic value of iodine-123- metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J 2001; 65: 155-160.
16. Imamura Y, Fukuyama T. Prognostic value of myocardial MIBG scintigraphy findings in patients with cardiomyopathy - importance of background correction for quantification of MIBG activity. Ann Nucl Med 2002; 16: 387-393.
17. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and non-failing hearts. J Nucl Cardiol 1998; 5: 579-590.
18. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyful G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999; 33: 759-766.
19. Hillege HL, Girbes ARJ, de Kam PJ, Boomsta F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210.
20. Kurata C, Wakabayashi Y, Shouda S, Okayama K, Yamamoto T, Ishikawa A, et al. Enhanced cardiac clearance of iodine-123-MIBG in chronic renal failure. J Nucl Med 1995; 36: 2037-2043.
21. Kurata C, Uehara A, Sugi T, Ishikawa A, Fujita K, Yonemura K, et al. Cardiac autonomic neuropathy in patients with chronic renal failure on hemodialysis. Nephron 2000; 84: 312-319.
22. Blake GM, Lewington VJ, Zivanovic MA, Ackery DM. Glomerular filtration rate and kinetics of I-123-metaiodobenzylguanidine. Eur J Nucl Med 1989; 15: 618-623.
23. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Lerey AS, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 955-962.
24. Braunwald E, Colucci WS, Grossman W. Clinical aspects of heart failure: high-output heart failure-pulmonary edema. In: Braunwald E, ed. Heart disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA; WB Saunders, 1997: 445-470.
25. Wafelman AR, Nortier YL, Rosing H, Maessen HJ, Taal BG, Hoefnagel CA, et al. Renal excretion of metaiodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance. Nucl Med Commun 1995; 16: 767-772.